Overview of drug treatment for paroxysmal supraventricular tachycardia in Taiwan emergency departments: Adenosine using trend from 2000 to 2012
| Autor: | Shih-Chang Hung, Hung-Chang Hung, Ling-Ling Liu, Kuei-Chuan Chan, Jong-Wen Huang, Ya-Hsin Li, Huan-Wen Hsu, Wen Yi Chao, Ya-Chin Li |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Tachycardia
Adenosine Digoxin business.industry medicine.medical_treatment Taiwan Catheter ablation Emergency Nursing Amiodarone Anesthesia Tachycardia Supraventricular Tachycardia Ventricular medicine Humans Verapamil Diltiazem medicine.symptom Emergency Service Hospital Tachycardia Paroxysmal Labetalol business medicine.drug |
| Zdroj: | Australasian Emergency Care. 25:224-228 |
| ISSN: | 2588-994X |
| Popis: | Background Before 2010, guidelines recommended adenosine 6, 12, and a repeat dose of 12 mg for paroxysmal supraventricular tachycardia (PSVT). After 2010, these doses were reduced to two. This study aims to outline adenosine using trend from 2000 to 2012 in Taiwan emergency departments (EDs). Methods This was an ecological study. PSVT were drawn from one million individuals of the National Health Insurance Database. The χ2 test was used to determine an association between different adenosine doses and other antiarrhythmic drugs (OADs), including verapamil, diltiazem, amiodarone, digoxin, and labetalol. Results There were 3361 PSVT visits from 2000 to 2012; 834 (24.8%) did not receive an antiarrhythmic drug, and 2527 (75.2%) did, either adenosine with/without OADs or OADs alone. The use of an OAD was significantly different between the adenosine 6–18 mg and 19 + mg groups. Conclusions Most PSVT episodes converted with adenosine within 18 mg, and the success conversion rate was 62.2%. It could be up to 65.2% if they received more. Of the patients who did not have their PSVT reverted with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect